Did You Know...
...that after Walter Hunt patented the safety pin in 1849, he sold the rights to it for $400?
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7419984 | Pyrimidines and uses thereof The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor-cells. ... | 09/02/2008 |
| 7399860 | Manufacture of polyglutamate-therapeutic agent conjugates The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes. ... | 07/15/2008 |
| 7291616 | Aryl triazines as LPAAT-β inhibitors and uses thereof The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells. ... | 11/06/2007 |
| 7247630 | Uses of tricyclic compounds Novel tricyclic compounds are disclosed having the general structure of Formulas I or II: were R1, R2 and R3 are defined in the written description of the invention. The compounds are useful for the treatment or ... | 07/24/2007 |
| 7208507 | Pyridines and uses thereof The invention relates to pyridines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells. ... | 04/24/2007 |
| 7199238 | LPAAT-β inhibitors and uses thereof The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for ... | 04/03/2007 |
| 7173041 | Polyglutamic acid-camptothecin conjugates and methods of preparation The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use. ... | 02/06/2007 |
| 7153864 | Polyglutamic acid-camptothecin conjugates and methods of preparation The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use. ... | 12/26/2006 |
| 7053096 | Compounds having selective hydrolytic potentials Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems. ... | 05/30/2006 |
| 7052891 | Human lysophoshatidic acid acyltransferase gamma-1 polypeptide Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase. ... | 05/30/2006 |
| 7045327 | Human lysophosphatidic acid acyltransferase gamma-2 polypeptide Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase. ... | 05/16/2006 |
| 6300487 | Mammalian lysophosphatidic acid acyltransferase Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.... | 10/09/2001 |
| 6133274 | Hydroxyl-containing bicyclic compounds Disclosed are therapeutic compounds having the formula: including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to se... | 10/17/2000 |
| 5929081 | Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF and VEGF There is disclosed a method for: (1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of ca... | 07/27/1999 |
